As per Future Market Insights, driven by rising cases of cancer and cardiovascular diseases, radiopharmaceutical market registered steady year-on-year growth at 4.90% CAGR in 2021.
DUBAI, United Arab Emirates, As per Future Market Insights (FMI), driven by rising cases of cancer and cardiovascular diseases, radiopharmaceutical market registered steady year-on-year growth at 4.90% CAGR in 2021.
Increasing development of radioisotopes to curb the cases of cancer have propelled the market demand, topping a valuation of US$ 6,107.2 Mn in 2021. Rising cases of prostate and breast cancer, especially in developed countries including the U.S., the U.K., and Germany, have increased the application of radiopharmaceuticals.
Request a report sample to gain comprehensive insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-1992
Government initiatives and research activities undertaken to develop advanced radioisotopes for the treatment of cancer and to develop novel therapeutics will boost the demand. Also, introduction of novel technologies such as Positron Emission Technology and others in nuclear imaging systems will bolster growth.
However, due to the global shutdown witnessed in the FQ-20 in response to the COVID-19 outbreak, growth declined considerably. Suspended production of radioisotopes and disruption in the research activities delayed the deployment of projects in the healthcare sector.
Although, with increasing development activities and increasing commercialization of radiopharmaceuticals by industry giants have picked up the pace for the growth of market. Alongside this, increasing cases of cancer will accelerate the development of nuclear medicines in the field of radiopharmaceuticals.
Increasing preference of non-invasive medical therapies and production of radioisotopes for the treatment is another factor that will stabilize the growth of radiopharmaceuticals market. Based on this, FMI projects the market is poised to expand at over 4.66% CAGR during the forecast period of 2021 and 2031.
For any Queries Related with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-1992
Key Takeaways from FMI’s Radiopharmaceuticals Market Study
- In terms of application, oncology will contribute over 50% of global market share owing to the rising prevalence of cancer across the globe.
- Cyclotrons are expected to be the primary source of radiopharmaceuticals, accounting for maximum market share
- Based on radioisotope type, technetium-99 will remain highly preferred radioisotope in the global radiopharmaceutical market
- The U.S. will retain its global dominance backed by the high cancer and cardiovascular cases rising in the country
- India will emerge as lucrative market owing to the favorable government initiatives promoting the radiopharmaceuticals market
- Germany and the U.K. are spearheading the growth of Europe market, which is projected to grow at over 4.9% CAGR
We Offer tailor-made Solutions to fit Your Requirements, Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-1992
Competitive Landscape
Leading radiopharmaceuticals market players are focusing on expanding their customer base through strategic mergers and acquisition. Increasing research and development activities to develop advanced radioisotopes for the cancer treatment is another core strategy adopted by leading players.
Top 5 players including Siemens AG, GE Healthcare, Curium, Lantheus Holdings Inc., and Eckert & Ziegler are dominating the global radiopharmaceuticals market, contributing over 90% of revenue share.
In March 2021, Novartis announced the commercialization and obtained the rights to develop the therapeutic applications of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc.
Explore FMI’s Extensive ongoing Coverage on Healthcare Domain
Radiotherapy Positioning Devices Market - The Radiotherapy positioning devices are used to position the patients during radiotherapy session. The patient positioning and immobilization are important during the radiation therapy treatment.
Tele Radiology Market - The teleradiology market is projected to register a CAGR of 15.3% during the forecast period, up from US$ 7.3 Bn in 2021 to reach a valuation of US$ 14.8 Bn by 2026.
Radioimmunotherapy Treatment Market - Cancer is a leading cause of death worldwide and is projected to rise with an estimated 11.5 million deaths in 2030. The most common cancer is lung cancer, accounting about 1.59 million deaths, other types of cancer include liver cancer, breast cancer, stomach cancer, liver cancer, etc.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/
Report: https://www.futuremarketinsights.com/reports/radiopharmaceuticals-market